Aoife Murray,Gillian Gough,Ana Cindrić,Frano Vučković,David Koschut,Vincenzo Borelli,Dražen J Petrović,Ana Bekavac,Ante Plećaš,Valentina Hribljan,Reinhard Brunmeir,Julija Jurić,Maja Pučić-Baković,Anita Slana,Helena Deriš,Azra Frkatović,Jűrgen Groet,Niamh L O'Brien,Hong Yu Chen,Yee Jie Yeap,Frederic Delom,Steven Havlicek,Luke Gammon,Sarah Hamburg,Carla Startin,Hana D'Souza,Dinko Mitrečić,Mijana Kero,Ljubica Odak,Božo Krušlin,Željka Krsnik,Ivica Kostović,Jia Nee Foo,Yuin-Han Loh,Norris Ray Dunn,Susana de la Luna,Tim Spector,Ingeborg Barišić,Michael S C Thomas,Andre Strydom,Claudio Franceschi,Gordan Lauc,Jasminka Krištić,Ivan Alić,Dean Nižetić,Dražen J. Petrović,Niamh L. O’Brien,Hana D’Souza,Michael S.C. Thomas

Abstract:BACKGROUND: People with Down syndrome (DS) show clinical signs of accelerated ageing. Causative mechanisms remain unknown and hypotheses range from the (essentially untreatable) amplified-chromosomal-instability explanation, to potential actions of individual supernumerary chromosome-21 genes. The latter explanation could open a route to therapeutic amelioration if the specific over-acting genes could be identified and their action toned-down.METHODS: Biological age was estimated through patterns of sugar molecules attached to plasma immunoglobulin-G (IgG-glycans, an established "biological-ageing-clock") in n = 246 individuals with DS from three European populations, clinically characterised for the presence of co-morbidities, and compared to n = 256 age-, sex- and demography-matched healthy controls. Isogenic human induced pluripotent stem cell (hiPSCs) models of full and partial trisomy-21 with CRISPR-Cas9 gene editing and two kinase inhibitors were studied prior and after differentiation to cerebral organoids.FINDINGS: Biological age in adults with DS is (on average) 18.4-19.1 years older than in chronological-age-matched controls independent of co-morbidities, and this shift remains constant throughout lifespan. Changes are detectable from early childhood, and do not require a supernumerary chromosome, but are seen in segmental duplication of only 31 genes, along with increased DNA damage and decreased levels of LaminB1 in nucleated blood cells. We demonstrate that these cell-autonomous phenotypes can be gene-dose-modelled and pharmacologically corrected in hiPSCs and derived cerebral organoids. Using isogenic hiPSC models we show that chromosome-21 gene DYRK1A overdose is sufficient and necessary to cause excess unrepaired DNA damage.INTERPRETATION: Explanation of hitherto observed accelerated ageing in DS as a developmental progeroid syndrome driven by DYRK1A overdose provides a target for early pharmacological preventative intervention strategies.FUNDING: Main funding came from the "Research Cooperability" Program of the Croatian Science Foundation funded by the European Union from the European Social Fund under the Operational Programme Efficient Human Resources 2014-2020, Project PZS-2019-02-4277, and the Wellcome Trust Grants 098330/Z/12/Z and 217199/Z/19/Z (UK). All other funding is described in details in the "Acknowledgements".

Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome

DYRK1A gene linked to heart defects in Down syndrome

Erratum: Genetic analysis of Down syndrome-associated heart defects in mice (Human Genetics DOI: 10.1007/s00439-011-0980-2)

Genetic analysis of Down syndrome-associated heart defects in mice

Human Chromosome 21 Orthologous Region on Mouse Chromosome 17 is a Major Determinant of Down Syndrome-Related Developmental Cognitive Deficits.

Genetic analysis of Down syndrome facilitated by mouse chromosome engineering.

Comprehensive phenotypic analysis of the Dp1Tyb mouse strain reveals a broad range of Down syndrome-related phenotypes

DYRK1A kinase triplication is the major cause of Otitis Media in Down Syndrome

Investigating brain alterations in the Dp1Tyb mouse model of Down syndrome

Abstract 12562: DYRK1A/PPARG/EGR1 Pathway Elicits Endothelial Dysfunctions and Predispose to Developing Pulmonary Hypertension in Down Syndrome

Genetic dissection of triplicated chromosome 21 orthologs yields varying skeletal traits in Down syndrome model mice

Interferon hyperactivity impairs cardiogenesis in Down syndrome via downregulation of canonical Wnt signaling

Isogenic Pairs of Induced-Pluripotent Stem-Derived Endothelial Cells Identify DYRK1A/PPARG/EGR1 Pathway is Responsible for Down Syndrome-Associated Pulmonary Hypertension.

Spermatogonial depletion and a spermatogenesis defect in the Dp(16)1Yey mouse model of Down syndrome.

Dystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype

A new mouse model for Down syndrome

Sex specific emergence of trisomic Dyrk1a-related skeletal phenotypes in the development of a Down syndrome mouse model

Nfat Dysregulation by Increased Dosage of Dscr1 and Dyrk1a on Chromosome 21

overdosage induces mid-face shortening through downregulation in Down syndrome models

Dose imbalance of DYRK1A kinase causes systemic progeroid status in Down syndrome by increasing the un-repaired DNA damage and reducing LaminB1 levels

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives